港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

映恩生物-B

195.700

+6.2003.27%

成交量：87.85萬

成交額：1.72億

市值：177.74億

市盈率：-4.92

高：200.000

開：193.000

低：186.800

收：189.500

52周最高：563.500

52周最低：158.500

股本：9,082.42萬

香港流通股本：9,082.42萬

量比：1.00

換手率：0.97%

股息：- -

股息率：- -

每股收益(LYR):-39.800

淨資產收益率：-1282.14%

總資產收益率：-9.61%

市淨率：6.28

市盈率(LYR):-4.92

市銷率: 8.23

資料載入中...

總覽公司新聞資訊公告

財報前瞻｜映恩生物-B回購與中期業績臨近，機構看多

異動解讀｜映恩生物-B盤中上漲5.12%，創新藥板塊活躍疊加中期業績臨近催化

異動解讀｜映恩生物-B盤中上漲5.22%，瑞銀首次覆蓋疊加中期業績臨近催化

映恩生物－Ｂ(09606)出現大手買入2.71萬股，成交價$198.0，涉資536.58萬

阿斯达克财经

異動解讀｜映恩生物-B盤中上漲5.56%，瑞銀首次覆蓋給予買入評級疊加板塊走強

瑞銀：映恩生物-B首次覆蓋給予「買入」評級目標價320港元

異動解讀｜映恩生物-B盤中下跌5.14%，報182.7港元

瑞銀：首次覆蓋映恩生物-B(09606.HK)予「買入」評級目標價320港元

《大行》瑞銀首次覆蓋映恩生物(09606.HK)予「買入」評級目標價320元

阿斯达克财经

映恩生物-B(09606)擬於2026年8月28日審議中期業績

【券商聚焦】招商證券首予映恩生物（09606）強烈推薦評級指ADC管線差異化優勢顯著

異動解讀｜映恩生物-B盤中上漲5.28%，生物科技板塊集體走強延續估值修復

異動解讀｜映恩生物-B盤中上漲5.09%，生物科技板塊整體走強帶動反彈延續

映恩生物-B更新2026年7月股份變動月報表，總股本增至91,224,314股

異動解讀｜映恩生物-B盤中上漲5.15%，創新藥板塊情緒回暖疊加突破性療法認定提振

異動解讀｜映恩生物-B盤中下跌5.23%，GSK競爭壓力與減持憂慮延續

一周港股牛熊榜 | 海致科技周漲40%問鼎牛榜榜首；清盤人重啓股權出售計劃，恒大物業周漲23%；偉祿科技暴跌33%，遭大股東減持12%

老虎资讯综合

映恩生物－Ｂ(09606)股價下跌5.038%，現價港幣$222.4

阿斯达克财经

【券商聚焦】中國銀河證券首予映恩生物(09606)推薦評級指其ADC管線梯隊完善

異動解讀｜映恩生物-B盤中下跌5.15%，報228.4港元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":195.7,"timestamp":1787645294008,"preClose":189.5,"halted":0,"volume":878542,"delay":0,"changeRate":0.03271767810026379,"floatShares":90824200,"shares":90824200,"eps":-39.8,"marketStatus":"已收盤","change":6.2,"latestTime":"08-25 16:08:14","open":193,"high":200,"low":186.8,"amount":172114685,"amplitude":0.069657,"askPrice":195.8,"askSize":100,"bidPrice":195.7,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-31.631,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1787707800000},"marketStatusCode":5,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":189.5,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"volumeRatio":0.99729,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90824200,"roa":"-9.61%","roe":"-1282.14%","lyrEps":-39.8,"volumeRatio":0.99729,"shares":90824200,"dividePrice":0,"high":200,"amplitude":0.069657,"preClose":189.5,"low":186.8,"week52Low":158.5,"pbRate":"6.28","psRate":"8.23","week52High":563.5,"institutionHeld":0,"latestPrice":195.7,"committee":0.666667,"eps":-39.8,"divideRate":0,"volume":878542,"delay":0,"ttmEps":-31.631,"open":193,"prevYearClose":298.2,"prevWeekClose":194.5,"prevMonthClose":181.8,"prevQuarterClose":181.2,"fiveDayClose":182.4,"twentyDayClose":227.8,"sixtyDayClose":225.6,"earningDate":1787846400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-08-28","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787880600000,"name":null,"time":"","dateTimestamp":1787846400000,"actualEps":null},{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":6,"updateTime":1783612800000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-08-24","current":-6.177484,"percent":0.924925,"low":-29.984477,"twenty":-16.330341,"median":-9.298112,"eighty":-6.878884,"high":-4.703556,"avg":-11.665482,"sd":6.231654,"marketCap":17140808253},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838},{"date":"2026-06-05","current":-5.374082,"twenty":-18.0452,"median":-9.575685,"eighty":-8.511806,"marketCap":16873830092},{"date":"2026-06-12","current":-5.36331,"twenty":-17.183112,"median":-9.557279,"eighty":-8.481744,"marketCap":16828616185},{"date":"2026-06-18","current":-5.321722,"twenty":-16.860136,"median":-9.537613,"eighty":-8.412993,"marketCap":16738188371},{"date":"2026-06-26","current":-4.703556,"twenty":-16.761475,"median":-9.522579,"eighty":-8.375473,"marketCap":14721648119},{"date":"2026-07-03","current":-6.212828,"twenty":-16.718804,"median":-9.508222,"eighty":-8.310046,"marketCap":19460065572},{"date":"2026-07-10","current":-6.457487,"twenty":-16.608112,"median":-9.462457,"eighty":-8.218812,"marketCap":20201573647},{"date":"2026-07-17","current":-6.192643,"twenty":-16.533051,"median":-9.445101,"eighty":-8.097368,"marketCap":19441980010},{"date":"2026-07-24","current":-6.744145,"twenty":-16.505793,"median":-9.428231,"eighty":-7.995787,"marketCap":21178194038},{"date":"2026-07-31","current":-5.225281,"twenty":-16.472851,"median":-9.409879,"eighty":-7.856069,"marketCap":16439776585},{"date":"2026-08-07","current":-5.555188,"twenty":-16.434203,"median":-9.398864,"eighty":-7.73561,"marketCap":17511664790},{"date":"2026-08-14","current":-5.519506,"twenty":-16.417169,"median":-9.342917,"eighty":-7.473767,"marketCap":17421211976},{"date":"2026-08-21","current":-5.561665,"twenty":-16.354018,"median":-9.310353,"eighty":-6.918832,"marketCap":17593072323},{"date":"2026-08-24","current":-5.420643,"twenty":-16.330341,"median":-9.298112,"eighty":-6.878884,"marketCap":17140808253}],"updateTime":1787643808442},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1100329397","title":"財報前瞻｜映恩生物-B回購與中期業績臨近，機構看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1100329397","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1100329397?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 10:35","pubTimestamp":1787279724,"startTime":"0","endTime":"0","summary":"映恩生物-B将于2026年8月28日盘后披露中期业绩，市场关注现金消耗与商业化推进节奏对收入与利润曲线的影响。目前缺少可验证的一致性季度预测，工具层面未提供本季度营收、毛利率、净利润或净利率、调整后每股收益的具体预测与同比数据。在可获得的机构研报与观点中，看多意见占比更高，占比100.00%。结合公司在2026年5月的回购举措与8月28日中期业绩披露的临近时间点，该机构倾向于将资本动作与业绩释放的潜在协同视作估值的催化因素。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜映恩生物-B回购与中期业绩临近，机构看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187275425","title":"異動解讀｜映恩生物-B盤中上漲5.12%，創新藥板塊活躍疊加中期業績臨近催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1187275425","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187275425?lang=zh_tw&edition=fundamental","pubTime":"2026-08-25 10:11","pubTimestamp":1787623904,"startTime":"0","endTime":"0","summary":"8月25日，映恩生物-B盘中上涨5.12%，报199.2港元/股，成交额2571.37万港元。消息面上，港股创新药板块整体活跃，国证港股通创新药指数上涨，板块内云顶新耀、荣昌生物等多股走强，映恩生物-B跟随板块共振。公司层面，瑞银近日首次覆盖给予\"买入\"评级，目标价320港元，较当前股价存在显著上行空间；招商证券、东吴证券、中国银河证券此前亦先后首次覆盖并给予积极评级。此外，公司将于8月28日披露中期业绩，叠加此前持续回购动作，机构看多情绪与业绩释放预期形成短期催化。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物盘中上涨，创新药板块共振催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161459117","title":"異動解讀｜映恩生物-B盤中上漲5.22%，瑞銀首次覆蓋疊加中期業績臨近催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1161459117","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161459117?lang=zh_tw&edition=fundamental","pubTime":"2026-08-21 10:37","pubTimestamp":1787279870,"startTime":"0","endTime":"0","summary":"8月21日，映恩生物-B盘中上涨5.22%，报197.5港元/股，成交额4669.57万港元。消息面上，瑞银近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价320港元，较当前股价存在约62%的上行空间。此外，招商证券、东吴证券、中国银河证券此前亦先后首次覆盖并给予积极评级。同时，公司将于8月28日披露中期业绩，叠加此前持续回购动作，机构看多情绪与业绩释放预期形成共振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物获瑞银首次看好，中期业绩临近催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660405898","title":"映恩生物－Ｂ(09606)出現大手買入2.71萬股，成交價$198.0，涉資536.58萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2660405898","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660405898?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 13:14","pubTimestamp":1787202840,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在下午01:14出现大手买入，成交量为2.71万，成交价为港币$198.0，涉资536.58万。至目前为止，股价升8.871%，今日最高价为$199.5，而最低价为$187.5，总成交量为88.937万股，总成交金额港币$1.729亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608204941/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2608204941/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","HK0000500386.USD","09606","LU2543165471.USD","HK0000252152.HKD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106943166","title":"異動解讀｜映恩生物-B盤中上漲5.56%，瑞銀首次覆蓋給予買入評級疊加板塊走強","url":"https://stock-news.laohu8.com/highlight/detail?id=1106943166","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106943166?lang=zh_tw&edition=fundamental","pubTime":"2026-08-20 09:44","pubTimestamp":1787190241,"startTime":"0","endTime":"0","summary":"8月20日，映恩生物-B盘中上涨5.56%，报194.5港元/股，成交额3997.93万港元。消息面上，瑞银近日首次覆盖映恩生物-B，给予\"买入\"评级，目标价320港元，较当前股价存在约65%的上行空间。瑞银指出公司现价仅对应0.7倍风险调整后峰值销售比率，远低于同业中位数的1.6倍，估值吸引。此外，招商证券、东吴证券、中国银河证券近期亦先后首次覆盖并给予积极评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.56%，瑞银首次覆盖给予买入评级叠加板块走强","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660101371","title":"瑞銀：映恩生物-B首次覆蓋給予「買入」評級 目標價320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660101371","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660101371?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 11:02","pubTimestamp":1786935720,"startTime":"0","endTime":"0","summary":"模拟交易客户端瑞银发布研报称，首次覆盖映恩生物-B，给予“买入”评级，基于风险调整后现金流折现估值，目标价320港元，对应1.2倍风险调整后峰值销售比率。映恩生物是一家专注于新型抗体药物偶联物研发的临床阶段生物科技公司。该行预计DB-1311将成为主要估值驱动力，预测其峰值销售达383亿元人民币，高于市场共识的286亿元人民币。该行预测2025年总收入（未调整）将由18亿元人民币升至2035年的228亿元人民币，EBITDA预计在2030年转正。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2026-08-17/doc-ininqtns0338953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09606","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193925469","title":"異動解讀｜映恩生物-B盤中下跌5.14%，報182.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1193925469","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193925469?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:51","pubTimestamp":1786931510,"startTime":"0","endTime":"0","summary":"8月17日，映恩生物-B盘中下跌5.14%，报182.7港元/股，成交额2591.9万港元。映恩生物-B所在的生物科技行业中，个股表现分化，康方生物跌6.67%，信达生物涨0.96%，百济神州涨0.85%，荣昌生物跌2.23%，三生制药跌3.42%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303、DB-1311、DB-1310、DB-1305等，覆盖乳腺癌、子宫内膜癌、肺癌等多个适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660061091","title":"瑞銀：首次覆蓋映恩生物-B(09606.HK)予「買入」評級 目標價320港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2660061091","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660061091?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 09:15","pubTimestamp":1786929349,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09606","BK1161","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659814819","title":"《大行》瑞銀首次覆蓋映恩生物(09606.HK)予「買入」評級  目標價320元","url":"https://stock-news.laohu8.com/highlight/detail?id=2659814819","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659814819?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 18:07","pubTimestamp":1786702020,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告，首次覆盖映恩生物-B，给予“买入”评级，基于风险调整后现金流折现估值，目标价320港元，对应1.2倍风险调整后峰值销售比率。映恩生物是一家专注于新型抗体药物偶联物研发的临床阶段生物科技公司。多个候选药物在研发进度上位居全球前三，并已与BioNTech、GSK、百济神州及Avenzo等全球制药公司建立合作，交易总值超过60亿美元。该行预测2025年总收入(未调整)将由18亿元人民币升至2035年的228亿元人民币，EBITDA预计在2030年转正。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250409114926459_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250409114926459_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538426/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1538426/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157327363","title":"映恩生物-B(09606)擬於2026年8月28日審議中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1157327363","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157327363?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 16:36","pubTimestamp":1786696594,"startTime":"0","endTime":"0","summary":"映恩生物-B（09606）8月14日公告，公司董事会将于2026年8月28日（星期五）召开会议，审议并批准截至2026年6月30日止六个月的未经审计中期业绩及其发布事宜。届时，董事会亦将处理其他相关事项。\n截至本公告日期，映恩生物-B董事会成员包括：  \n1. 执行董事：朱忠远博士（董事会主席兼首席执行官）、张韶壬先生、花海清博士；  \n2. 非执行董事：蔡志洋先生、余涛博士；  \n3. 独立非执行董事：谢东先生、高凤勇先生、揣姝茵女士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658921431","title":"【券商聚焦】招商證券首予映恩生物（09606）強烈推薦評級 指ADC管線差異化優勢顯著","url":"https://stock-news.laohu8.com/highlight/detail?id=2658921431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658921431?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 14:39","pubTimestamp":1786516786,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招商证券发布研报指，映恩生物 凭借四大自主知识产权ADC技术平台，构建了覆盖肿瘤与自免疾病、从1.0到3.0全梯度的差异化管线。DB-1303针对二线及以上HER2阳性乳腺癌的III期研究已达PFS主要终点，中国BLA于2026年4月获NMPA受理；其子宫内膜癌适应症获中美突破性疗法认定，为全球少数覆盖全HER2表达水平的HER2 ADC。首次覆盖，给予“强烈推荐”投资评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","09606","ADC","06099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106331638","title":"異動解讀｜映恩生物-B盤中上漲5.28%，生物科技板塊集體走強延續估值修復","url":"https://stock-news.laohu8.com/highlight/detail?id=1106331638","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106331638?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 11:52","pubTimestamp":1786420323,"startTime":"0","endTime":"0","summary":"8月11日，映恩生物-B盘中上涨5.28%，报205.4港元，成交额1.03亿港元。该股此前因GSK竞争压力于7月30日大跌后持续修复，本次上涨主要受生物科技板块集体走强带动。消息面上，同行业个股今日普涨，百济神州涨4.41%、再鼎医药涨4.6%、康方生物涨2.76%，板块情绪延续回暖。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172376984","title":"異動解讀｜映恩生物-B盤中上漲5.09%，生物科技板塊整體走強帶動反彈延續","url":"https://stock-news.laohu8.com/highlight/detail?id=1172376984","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172376984?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 14:17","pubTimestamp":1786083478,"startTime":"0","endTime":"0","summary":"8月7日，映恩生物-B盘中上涨5.09%，报191.9港元，成交额1.48亿港元。该股此前因GSK竞争压力于7月30日大跌13.7%，近期逐步企稳修复。消息面上，港股生物科技板块今日整体走强，荣昌生物涨9.12%、药捷安康-B涨6.94%、百济神州涨5.16%、康方生物涨4.06%，板块情绪显著回暖带动映恩生物跟涨。此外，公司核心管线B7-H3 ADC此前获NMPA突破性疗法认定，科创板IPO申请已获上交所受理并进入已问询阶段，多家券商给予\"买入\"评级，基本面利好持续积累支撑估值修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.09%，生物科技板块整体走强带动反弹延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160159290","title":"映恩生物-B更新2026年7月股份變動月報表，總股本增至91,224,314股","url":"https://stock-news.laohu8.com/highlight/detail?id=1160159290","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160159290?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 16:49","pubTimestamp":1785919773,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年8月5日披露2026年7月股份变动月报表。报告显示，截至本月末，公司法定注册股本维持在200,000,000股普通股不变，每股面值0.0001美元，法定注册股本总额保持在20,000美元。公司表示，其已符合香港联交所主板上市规则相关的公众持股量最低要求。公司亦确认，其在本月的所有股份发行或库存股出售与转让事宜均严格遵照香港联交所《上市规则》和相关法律法规的规定执行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123746970","title":"異動解讀｜映恩生物-B盤中上漲5.15%，創新藥板塊情緒回暖疊加突破性療法認定提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1123746970","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123746970?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 13:23","pubTimestamp":1785820995,"startTime":"0","endTime":"0","summary":"8月4日，映恩生物-B盘中上涨5.15%，报189.8港元，成交额1.3亿港元。此前该股因GSK竞争压力连续调整，7月30日大跌13.7%，8月3日再跌5.23%，当前出现明显反弹。消息面上，药明康德半年报业绩超预期并全面上调全年指引，显著提振创新药产业链信心，港股通创新药ETF整体走强，映恩生物-B受板块情绪带动。此外，公司核心管线B7-H3 ADC Elfe-D近期获NMPA突破性疗法认定，海内外均获监管认可，多家券商给予\"买入\"评级，基本面支撑逐步修复市场信心。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"映恩生物-B盘中上涨5.15%，创新药板块情绪回暖叠加突破性疗法认定提振","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174620861","title":"異動解讀｜映恩生物-B盤中下跌5.23%，GSK競爭壓力與減持憂慮延續","url":"https://stock-news.laohu8.com/highlight/detail?id=1174620861","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174620861?lang=zh_tw&edition=fundamental","pubTime":"2026-08-03 09:45","pubTimestamp":1785721512,"startTime":"0","endTime":"0","summary":"8月3日，映恩生物-B盘中下跌5.23%，报172.6港元，成交额2716.64万港元。消息面上，此前葛兰素史克（GSK）在半年报中大幅提升其B7-H3 ADC管线Ris-Rez的战略优先级，将其定义为2031年后肿瘤业务增长核心，直接冲击映恩生物核心管线DB-1311的竞争格局。该股7月30日已大跌13.7%，当前延续调整态势。此外，市场对基石投资者解禁后的减持压力亦存担忧，叠加公司行权Co-Co模式后需持续投入大量研发资金，资金链压力受到关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181533841","title":"一周港股牛熊榜 | 海致科技周漲40%問鼎牛榜榜首；清盤人重啓股權出售計劃，恒大物業周漲23%；偉祿科技暴跌33%，遭大股東減持12%","url":"https://stock-news.laohu8.com/highlight/detail?id=1181533841","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181533841?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 19:35","pubTimestamp":1785497713,"startTime":"0","endTime":"0","summary":"7月全月恒指累升3,003点或13.1%。该股7月21日盘中一度跌33%至111港元，此前7月17日尚报203.60港元。张先生通过其或透过其控制的实体计划于未来6个月增持价值介乎3.0亿港元至6.0亿港元的股份。下一步，计划邀请潜在买方对集团进行尽职调查。出售事项后，美林控股持有7.33亿股股份，占本公司已发行股本总额约50.83%。美林控股进一步告知董事会，据其深知、尽悉及确信，于出售事项前，买方为本公司及其关连人士的独立第三方","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02687","06166","09606","01196","06666","09903","01888","01783","06887","02706"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092391","title":"映恩生物－Ｂ(09606)股價下跌5.038%，現價港幣$222.4","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092391","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092391?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 14:04","pubTimestamp":1785132240,"startTime":"0","endTime":"0","summary":"[下跌股]映恩生物－Ｂ(09606) 股价在下午02:03比前收市价下跌5.038%，现股价为港币$222.4。至目前为止，今日最高价为$237.0，而最低价为$222.4。总成交量为29.95万股，总成交金额为港币$6.852千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607272189/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2607272189/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2543165471.USD","HK0000252152.HKD","09606","BK1161","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653221532","title":"【券商聚焦】中國銀河證券首予映恩生物(09606)推薦評級 指其ADC管線梯隊完善","url":"https://stock-news.laohu8.com/highlight/detail?id=2653221532","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653221532?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 15:31","pubTimestamp":1784619085,"startTime":"0","endTime":"0","summary":"DB-1303安全性可控，HER2阳性乳腺癌已递交上市申请，填补HER2低表达患者治疗空白。DB-1310针对EGFR靶向耐药肺癌，多线人群ORR达43.5%。DB-1305联合双抗一线三阴性乳腺癌确认超高缓解率。创新管线中，全球首创自免ADC DB-2304靶向BDCA2，直击红斑狼疮未满足临床需求，已推进至IIa期。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmUwNDEzZDkyZTQxMjdjZGQ1ZTFlYjEwODUyNTc4Njg4Nw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986406","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","161027","601881","09606","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111245137","title":"異動解讀｜映恩生物-B盤中下跌5.15%，報228.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111245137","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111245137?lang=zh_tw&edition=fundamental","pubTime":"2026-07-21 10:15","pubTimestamp":1784600144,"startTime":"0","endTime":"0","summary":"7月21日，映恩生物-B盘中下跌5.15%，报228.4港元/股，成交额5300.47万港元。映恩生物-B所在的生物科技行业整体走弱，个股中，百济神州跌2.19%，康方生物跌3.05%，信达生物跌2.49%，科伦博泰生物跌0.99%，三生制药跌2.24%。映恩生物是一家主要从事临床阶段生物制药的投资控股公司，致力于为癌症和自身免疫性疾病等患者研发抗体偶联药物创新药物，主要候选药物产品包括DB-1303/BNT323、DB-1311/BNT324、DB-1310等，公司主要在国内和国外市场开展业务。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":136,"code":"91000000","status":"200"}]}}